The result of the Cancer Drug Fund panel's re-evaluation exercise has just been published. The good news for CML patients in chronic and accelerated phases, access to TKIs dasatinib, bosutinib remains unchanged, however the panel have delisted dasatinib and bosutinib for use in blastic phase CML.
Ponatinib does not have an indication for use in blast phase, but remains unchanged in its indication for patients with the T315i mutation.
To date (up to end of Sept 2014) there is no record of a successful application being made for bosutinib for use in blast phase.
Regarding dasatinib, there were 17 successful applications made in the 18 month from April 2013 to end of Sept 2014 which does indicate that clinicians think it is useful in myeloid blast phase CML.
However, we are disappointed that dasatinib has been delisted for use in a sub-group of patients whose disease transforms into a lymphoid blast phase (rather than myeloid) CML.
http://www.england.nhs.uk/wp-content/uploads/2015/01/ncdf-list-dec14.pdf